Axovia Therapeutics is dedicated to the research and development of novel AAV gene therapies that target key aspects of ciliopathies, addressing the devastating impact of the disease head-on for patients, their families and caregivers. Axovia is currently developing therapies for patients with mutations in the BBS1 gene which manifests as Bardet Biedl Syndrome. Our initial goal is to halt the progression of BBS by targeting the most debilitating aspects of the neurological, metabolic and retinal dysfunctions.
Employees: 11-50
Founded date: 2020
Investors 1
| Date | Name | Website |
| 27.10.2023 | ALSA Ventu... | alsaventur... |
Mentions in press and media 1
| Date | Title | Description |
| 18.09.2023 | ALSA Ventures announces the acquisition of Axovia Therapeutics Inc and the launch of a new portfolio company Axovia Therapeutics Ltd. | · Developing the first gene therapy to treat diseases caused by cilia dysfunction |